U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H12N2O3
Molecular Weight 208.2139
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PICAMILON

SMILES

OC(=O)CCCNC(=O)C1=CC=CN=C1

InChI

InChIKey=NAJVRARAUNYNDX-UHFFFAOYSA-N
InChI=1S/C10H12N2O3/c13-9(14)4-2-6-12-10(15)8-3-1-5-11-7-8/h1,3,5,7H,2,4,6H2,(H,12,15)(H,13,14)

HIDE SMILES / InChI

Molecular Formula C10H12N2O3
Molecular Weight 208.2139
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Picamilon (also known as N-nicotinoyl-GABA, Pycamilon, and Pikamilon) is a drug formed by a synthetic combination of niacin and GABA. It was developed in the Soviet Union in 1969 and further studied in both Russia and Japan as a prodrug of GABA. Picamilon permeated the blood-brain barrier and then is hydrolyzed into GABA and niacin. The released GABA, in theory, would activate GABA receptors potentially producing an anxiolytic response. The second released component, niacin, is a vasodilator. Today picamilon is sold in Russia as a prescription drug and is used for the treatment of a variety of illnesses and disorders, ranging from depression to a migraine, neuro infections, senile psychosis, certain types of glaucoma, and even acute alcohol intoxication. As of 2015, the FDA classified picamilon as a substance that does not meet the requirements of a dietary supplement and is therefore no longer permitted to be sold in the United States.

Originator

Sources: Pharmacotherapeutica, 1950-1959 (1963), 31-48.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Пикамилон

Approved Use

Indication of the drug Picamylon Violations of cerebral circulation (acute ischemic, subacute and recovery periods of ischemic stroke, chronic cerebral circulatory failure), vegetovascular dystonia, asthenia, depression, senile psychosis; alcoholism (the period of withdrawal), acute alcohol intoxication, migraine, craniocerebral trauma, neuroinfections, primary open-angle glaucoma (for stabilization of visual function).
Primary
Пикамилон

Approved Use

Indication of the drug Picamylon Violations of cerebral circulation (acute ischemic, subacute and recovery periods of ischemic stroke, chronic cerebral circulatory failure), vegetovascular dystonia, asthenia, depression, senile psychosis; alcoholism (the period of withdrawal), acute alcohol intoxication, migraine, craniocerebral trauma, neuroinfections, primary open-angle glaucoma (for stabilization of visual function).
Primary
Пикамилон

Approved Use

Indication of the drug Picamylon Violations of cerebral circulation (acute ischemic, subacute and recovery periods of ischemic stroke, chronic cerebral circulatory failure), vegetovascular dystonia, asthenia, depression, senile psychosis; alcoholism (the period of withdrawal), acute alcohol intoxication, migraine, craniocerebral trauma, neuroinfections, primary open-angle glaucoma (for stabilization of visual function).
Primary
Пикамилон

Approved Use

Indication of the drug Picamylon Violations of cerebral circulation (acute ischemic, subacute and recovery periods of ischemic stroke, chronic cerebral circulatory failure), vegetovascular dystonia, asthenia, depression, senile psychosis; alcoholism (the period of withdrawal), acute alcohol intoxication, migraine, craniocerebral trauma, neuroinfections, primary open-angle glaucoma (for stabilization of visual function).
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

In Vivo Use Guide
cerebrovascular diseases - 0,02-0,05 g 2-3 times for 1-2 months; depression - on 0,04-0,2 g in 2-3 receptions in day within 1,5-3 months; as an anti-asthenic and tranquilizing agent - 0,04-0,08 g per day, in some cases - up to 0,2-0,3 g per day for 1-1,5 months; alcoholism: 0.1-0.15 g per day (course - 6-7 days)
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:42:15 UTC 2023
Edited
by admin
on Fri Dec 15 19:42:15 UTC 2023
Record UNII
0S5N9SEK4N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PICAMILON
Common Name English
PIKATROPIN
Common Name English
PIKAMILONE
Common Name English
PYCAMILON
Common Name English
NICOTINOYL-.GAMMA.-AMINOBUTYRIC ACID
Systematic Name English
4-(PYRIDINE-3-CARBONYLAMINO)BUTANOIC ACID
Systematic Name English
NICOTINOYL-GABA
Common Name English
BUTANOIC ACID, 4-((3-PYRIDINYLCARBONYL)AMINO)-
Systematic Name English
PIKAMILON
Common Name English
Classification Tree Code System Code
DSLD 2497 (Number of products:99)
Created by admin on Fri Dec 15 19:42:16 UTC 2023 , Edited by admin on Fri Dec 15 19:42:16 UTC 2023
Code System Code Type Description
CAS
34562-97-5
Created by admin on Fri Dec 15 19:42:16 UTC 2023 , Edited by admin on Fri Dec 15 19:42:16 UTC 2023
PRIMARY
FDA UNII
0S5N9SEK4N
Created by admin on Fri Dec 15 19:42:16 UTC 2023 , Edited by admin on Fri Dec 15 19:42:16 UTC 2023
PRIMARY
PUBCHEM
60608
Created by admin on Fri Dec 15 19:42:16 UTC 2023 , Edited by admin on Fri Dec 15 19:42:16 UTC 2023
PRIMARY
WIKIPEDIA
Nicotinoyl-GABA
Created by admin on Fri Dec 15 19:42:16 UTC 2023 , Edited by admin on Fri Dec 15 19:42:16 UTC 2023
PRIMARY
EPA CompTox
DTXSID40188098
Created by admin on Fri Dec 15 19:42:16 UTC 2023 , Edited by admin on Fri Dec 15 19:42:16 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
HELPS WITH PENETRATION TO CNS